Bjørn Dalhus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bjørn Dalhus has a total of 138 co-authors. Here are the top co-authors by number of shared publications:
- Ajay Yadav
Department of Molecular Medicine, University of Oslo, Institute of Basic Medical Sciences, Oslo, Norway
11 shared publications - Hanne Røland Hagland
Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, Stavanger, Norway
11 shared publications - Kjetil Hestdal
Caedo Oncology AS, Oslo, Norway
11 shared publications - Liza E. Diomande
Caedo Oncology AS, Oslo, Norway
11 shared publications - Nina Richartz
Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
11 shared publications - Rolf D. Pettersen
Caedo Oncology AS, Oslo, Norway
11 shared publications
Latest Publications
- Open Access
- 1 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Computational and Structural Biotechnology Journal
- Vol. 35 (1)
SMITracker: An Interactive Platform for Tracking and Analysis of Single-Molecule Interactions with Linear Substrates
Understanding the interactions of proteins with macromolecular substrates such as DNA, microtubules, and actin filaments is critically important in molecular biology and beyond. Single-molecule experiments provide unprecedented insight into the dynamics of these interactions. However, efficient analysis of large datasets generated by such experiments remains a major challenge. Specifically, in single-molecule experiments that involve scanning of such linear substrates, the absence of a comprehensive and effective system for detecting interactions among millions of frames of high-frequency imaging data and excluding noise without bias hampers research productivity and data quality. To address these limitations, we introduce “Single-Molecule Interaction Tracker (SMITracker)”, an interactive analysis platform designed to enable efficient, accurate, and scalable detection of single-molecule interaction events. The protocol begins with raw image data obtained from single-molecule experiments, which undergoes preprocessing and is transformed into a structured dataset, suitable for processing in R. Using an automatic trajectory detection algorithm and a uniform noise exclusion model, the target data are detected and organized for further analysis. Final outputs include comprehensive diffusion analysis and informative visualization, enabling side-by-side comparison of different proteins and/or experimental conditions. SMITracker is available as an R package for R users and as a Docker image for non-R users, offering a highly effective and convenient solution to the common challenges in analyzing data from single-molecule experiments.
- 1 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Computational and Structural Biotechnology Journal
- Vol. 35 (1)
Open AccessSMITracker: An Interactive Platform for Tracking and Analysis of Single-Molecule Interactions with Linear Substrates
Understanding the interactions of proteins with macromolecular substrates such as DNA, microtubules, and actin filaments is critically important in molecular biology and beyond. Single-molecule experiments provide unprecedented insight into the dynamics of these interactions. However, efficient analysis of large datasets generated by such experiments remains a major challenge. Specifically, in single-molecule experiments that involve scanning of such linear substrates, the absence of a comprehensive and effective system for detecting interactions among millions of frames of high-frequency imaging data and excluding noise without bias hampers research productivity and data quality. To address these limitations, we introduce “Single-Molecule Interaction Tracker (SMITracker)”, an interactive analysis platform designed to enable efficient, accurate, and scalable detection of single-molecule interaction events. The protocol begins with raw image data obtained from single-molecule experiments, which undergoes preprocessing and is transformed into a structured dataset, suitable for processing in R. Using an automatic trajectory detection algorithm and a uniform noise exclusion model, the target data are detected and organized for further analysis. Final outputs include comprehensive diffusion analysis and informative visualization, enabling side-by-side comparison of different proteins and/or experimental conditions. SMITracker is available as an R package for R users and as a Docker image for non-R users, offering a highly effective and convenient solution to the common challenges in analyzing data from single-molecule experiments.
- Open Access
Structure-function studies on the serine protease domain of Factor VII activating protease (FSAP)
Factor VII activating protease (FSAP) is a circulating serine protease involved in stroke pathophysiology. This effect is likely mediated by the cleavage of substrates such as fibrinogen and extracellular histones. Our goal was to modify FSAP properties through mutagenesis to explore its different functions. Therefore, we expressed the serine protease domain (SPD) of FSAP with mutations and measured the cleavage of chromogenic substrate (S-2288), pro-urokinase (uPA), histones, and fibrinogen, as well as their inhibition by aprotinin, tissue factor pathway inhibitor (TFPI), and C1 inhibitor (C1Inh). Mutations are denoted using chymotrypsin numbering. Mutants KRHK63-65SSSS and K63aA/R63cA in the 60-loop were resistant to TFPI but not to aprotinin or C1Inh. Cleavage of pro-uPA and fibrinogen decreased, while histone and S-2288 cleavage remained normal. Mutants E96S, EDE96-99SSS, and D173A/E99S in the 99-loop produced a protease with reduced cleavage of histones and fibrinogen. EDE96-99SSS showed resistance to aprotinin, TFPI, and C1Inh, had lower affinity for S-2288, and exhibited less pro-uPA activation. The Q192D mutation was resistant to inhibition by aprotinin, TFPI, and C1Inh, but substrate cleavage remained unaffected. E218A was resistant to C1Inh inhibition but not to aprotinin or TFPI and showed normal substrate cleavage. R84S was resistant to aprotinin and TFPI but not C1Inh, with normal substrate cleavage. TFPI and C1Inh inhibited full-length FSAP more effectively than SPD-FSAP, though cleavage of histones and fibrinogen was more efficient with SPD-FSAP. These findings will enhance the understanding of the functional landscape of SPD-FSAP and help in developing mutants with altered properties to investigate FSAP functions.
Open AccessStructure-function studies on the serine protease domain of Factor VII activating protease (FSAP)
Factor VII activating protease (FSAP) is a circulating serine protease involved in stroke pathophysiology. This effect is likely mediated by the cleavage of substrates such as fibrinogen and extracellular histones. Our goal was to modify FSAP properties through mutagenesis to explore its different functions. Therefore, we expressed the serine protease domain (SPD) of FSAP with mutations and measured the cleavage of chromogenic substrate (S-2288), pro-urokinase (uPA), histones, and fibrinogen, as well as their inhibition by aprotinin, tissue factor pathway inhibitor (TFPI), and C1 inhibitor (C1Inh). Mutations are denoted using chymotrypsin numbering. Mutants KRHK63-65SSSS and K63aA/R63cA in the 60-loop were resistant to TFPI but not to aprotinin or C1Inh. Cleavage of pro-uPA and fibrinogen decreased, while histone and S-2288 cleavage remained normal. Mutants E96S, EDE96-99SSS, and D173A/E99S in the 99-loop produced a protease with reduced cleavage of histones and fibrinogen. EDE96-99SSS showed resistance to aprotinin, TFPI, and C1Inh, had lower affinity for S-2288, and exhibited less pro-uPA activation. The Q192D mutation was resistant to inhibition by aprotinin, TFPI, and C1Inh, but substrate cleavage remained unaffected. E218A was resistant to C1Inh inhibition but not to aprotinin or TFPI and showed normal substrate cleavage. R84S was resistant to aprotinin and TFPI but not C1Inh, with normal substrate cleavage. TFPI and C1Inh inhibited full-length FSAP more effectively than SPD-FSAP, though cleavage of histones and fibrinogen was more efficient with SPD-FSAP. These findings will enhance the understanding of the functional landscape of SPD-FSAP and help in developing mutants with altered properties to investigate FSAP functions.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile
Induction of hemagglutination by the various anti-CD47 mAbs. Incubation of freshly isolated RBCs (2% v/v in PBS) with increasing concentrations of the indicated anti-CD47 mAbs, or human IgG4 and IgG2 isotype control. A small punctate circle indicates no hemagglutination, while a diffuse hazy pattern indicates hemagglutination.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile
Induction of hemagglutination by the various anti-CD47 mAbs. Incubation of freshly isolated RBCs (2% v/v in PBS) with increasing concentrations of the indicated anti-CD47 mAbs, or human IgG4 and IgG2 isotype control. A small punctate circle indicates no hemagglutination, while a diffuse hazy pattern indicates hemagglutination.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile
CO-005 retains the dual functionality of CO-001 in various hematological cancer cell lines. (A) PCCD in MOLT-4, Reh, and CCRF-CEM cell lines after 3 hours of treatment with CO-005 (0.1 and 1 µg/ml. (B) Phagocytosis activity of CO-005 (1 μg/ml) in various hematological cell lines using DiO-labelled RAW264.7 macrophages. (C) CellTrace-labelled Jurkat cells or KG-1a cells (5×105 cells/ml) were co-cultured with DiO-labelled human macrophages differentiated from human PBMCs derived from three healthy human donors and treated with the indicated concentrations of CO-005 or 1 μg/ml of IgG4 for 2 hours. (B and C) Phagocytosed target cells were analyzed by flow cytometry as % Celltrace+DiO+ cells. (A-C) Data represent the mean ± S.D. Significance was determined by ANOVA analysis *p<0.01 relative to isotype control, n = 3-5.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile
CO-005 retains the dual functionality of CO-001 in various hematological cancer cell lines. (A) PCCD in MOLT-4, Reh, and CCRF-CEM cell lines after 3 hours of treatment with CO-005 (0.1 and 1 µg/ml. (B) Phagocytosis activity of CO-005 (1 μg/ml) in various hematological cell lines using DiO-labelled RAW264.7 macrophages. (C) CellTrace-labelled Jurkat cells or KG-1a cells (5×105 cells/ml) were co-cultured with DiO-labelled human macrophages differentiated from human PBMCs derived from three healthy human donors and treated with the indicated concentrations of CO-005 or 1 μg/ml of IgG4 for 2 hours. (B and C) Phagocytosed target cells were analyzed by flow cytometry as % Celltrace+DiO+ cells. (A-C) Data represent the mean ± S.D. Significance was determined by ANOVA analysis *p<0.01 relative to isotype control, n = 3-5.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile
Induction of PCCD and phagocytosis by CO-001 in various hematological cell lines.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile
Induction of PCCD and phagocytosis by CO-001 in various hematological cell lines.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile
CO-005 does not bind to murine CD47. The binding of CO-005 to murine CD47 (mCD47) was tested using bone marrow cells harvested from NSG mice. NSG bone marrow cells were incubated with CO-005, Magrolimab, human IgG4 isotype control, miap301 (murine anti-CD47 antibody), or rat IgG2a control at increasing concentrations. Binding was measured using a PE-conjugated Goat anti-human IgG Fc (for HuIgG4, CO-005, and Magrolimab) or Goat anti-Rat (for RatIgG2a and miap301) secondary antibody.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile
CO-005 does not bind to murine CD47. The binding of CO-005 to murine CD47 (mCD47) was tested using bone marrow cells harvested from NSG mice. NSG bone marrow cells were incubated with CO-005, Magrolimab, human IgG4 isotype control, miap301 (murine anti-CD47 antibody), or rat IgG2a control at increasing concentrations. Binding was measured using a PE-conjugated Goat anti-human IgG Fc (for HuIgG4, CO-005, and Magrolimab) or Goat anti-Rat (for RatIgG2a and miap301) secondary antibody.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile
Induction of hemagglutination by the humanized versions of CO-001. Incubation of freshly isolated RBCs (2% v/v in PBS) with increasing concentrations of CO-002 candidates A-K, or human IgG4 isotype control. A small punctate circle indicates no hemagglutination, while a diffuse hazy pattern indicates hemagglutination.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile
Induction of hemagglutination by the humanized versions of CO-001. Incubation of freshly isolated RBCs (2% v/v in PBS) with increasing concentrations of CO-002 candidates A-K, or human IgG4 isotype control. A small punctate circle indicates no hemagglutination, while a diffuse hazy pattern indicates hemagglutination.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile
Detailed list of the fluorophore-conjugated antibodies and reagents used in immune cell phenotyping by flow cytometry experiments. All materials were purchased from Thermo Fisher Scientific.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile
Detailed list of the fluorophore-conjugated antibodies and reagents used in immune cell phenotyping by flow cytometry experiments. All materials were purchased from Thermo Fisher Scientific.
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile
Induction of phagocytosis and PCCD by the humanized versions of CO-001 in Jurkat cells. (A) Phagocytosis activity of humanized versions of CO-001 (1 μg/ml) in Jurkat cell lines using DiO-labelled RAW264.7 macrophages. Phagocytosed target cells were analyzed by flow cytometry as % Celltrace+DiO+ cells (B) Jurkat cells (5×105 cells/ml) were incubated with 1 (left panel) or 10 (right panel) µg/ml CO-002 versions A-L for 3 hours, followed by Annexin V and 7-AAD staining. The cells that stained positive for Annexin V were undergoing PCCD. Data are presented as the mean ± S.D. Significance was determined by ANOVA analysis *p<0.05 relative to isotype control, n = 1 (upper panel), 3 (lower panel).
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile
Induction of phagocytosis and PCCD by the humanized versions of CO-001 in Jurkat cells. (A) Phagocytosis activity of humanized versions of CO-001 (1 μg/ml) in Jurkat cell lines using DiO-labelled RAW264.7 macrophages. Phagocytosed target cells were analyzed by flow cytometry as % Celltrace+DiO+ cells (B) Jurkat cells (5×105 cells/ml) were incubated with 1 (left panel) or 10 (right panel) µg/ml CO-002 versions A-L for 3 hours, followed by Annexin V and 7-AAD staining. The cells that stained positive for Annexin V were undergoing PCCD. Data are presented as the mean ± S.D. Significance was determined by ANOVA analysis *p<0.05 relative to isotype control, n = 1 (upper panel), 3 (lower panel).
- Open Access
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Data from Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile
Therapeutic anti-CD47 monoclonal antibodies (mAbs) are designed to block the CD47–SIRPα checkpoint and promote immune-mediated recognition and elimination of cancer cells. However, current anti-CD47 mAbs have limitations, including off-tumor toxicity and reduced effectiveness in advanced cancers. Additionally, CD47 serves as a death receptor that mediates programmed cancer cell death (PCCD), a mechanism that has not been fully explored in current therapies. In this study, we introduce CO-001, a chimeric bifunctional IgG4 mAb, and its optimized variant CO-005, a bivalent humanized single-chain fragment variable–fragment crystallizable fusion protein. Both CO-001 and CO-005 promoted phagocytosis and PCCD. CO-005, specifically engineered to overcome the safety limitations associated with anti-CD47 antibodies, demonstrates a superior hematologic safety profile in vitro and ex vivo compared with benchmark anti-CD47 antibodies. Notably, CO-005 exhibited no binding to red blood cells, limited binding to white blood cells, and showed no hemagglutination activity. In preclinical models, CO-005 demonstrated potent antitumor activity in B-cell precursor acute lymphoblastic leukemia and Raji lymphoma xenograft models through the dual action of PCCD induction and enhancement of phagocytosis. The ability of CO-005 to trigger strong PCCD while preserving conventional immune responses provides a novel and promising approach for CD47-targeted cancer therapy. Its favorable safety profile, observed in both in vitro and ex vivo studies, positions CO-005 as a promising candidate with potential therapeutic advantages over existing anti-CD47 treatments.
- 4 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile
Therapeutic anti-CD47 monoclonal antibodies (mAbs) are designed to block the CD47–SIRPα checkpoint and promote immune-mediated recognition and elimination of cancer cells. However, current anti-CD47 mAbs have limitations, including off-tumor toxicity and reduced effectiveness in advanced cancers. Additionally, CD47 serves as a death receptor that mediates programmed cancer cell death (PCCD), a mechanism that has not been fully explored in current therapies. In this study, we introduce CO-001, a chimeric bifunctional IgG4 mAb, and its optimized variant CO-005, a bivalent humanized single-chain fragment variable–fragment crystallizable fusion protein. Both CO-001 and CO-005 promoted phagocytosis and PCCD. CO-005, specifically engineered to overcome the safety limitations associated with anti-CD47 antibodies, demonstrates a superior hematologic safety profile in vitro and ex vivo compared with benchmark anti-CD47 antibodies. Notably, CO-005 exhibited no binding to red blood cells, limited binding to white blood cells, and showed no hemagglutination activity. In preclinical models, CO-005 demonstrated potent antitumor activity in B-cell precursor acute lymphoblastic leukemia and Raji lymphoma xenograft models through the dual action of PCCD induction and enhancement of phagocytosis. The ability of CO-005 to trigger strong PCCD while preserving conventional immune responses provides a novel and promising approach for CD47-targeted cancer therapy. Its favorable safety profile, observed in both in vitro and ex vivo studies, positions CO-005 as a promising candidate with potential therapeutic advantages over existing anti-CD47 treatments.